Recent work using an alternative UCHL1 inhibitor, IMP-1710, revealed a reduction of expression of profibrogenic markers in fibroblasts isolated from patients with idiopathic pulmonary fibrosis, demonstrating the importance of UCHL1 signalling in fibrosis [6]. This evidence concerns the gene UCHL1 and idiopathic pulmonary fibrosis.